Price movement over the last 24 hours
Alcon AG vs TORM plc — how do they compare? Alcon AG trades at $66.96 (market cap $32.69B), while TORM plc trades at $28.72 (market cap $2.87B). The key difference: Alcon AG is far larger — about 11.4× TORM plc's market cap, and TORM plc pays the higher dividend (9.87%). Which is the better fit depends on your goals.
| ALC | TRMD | |
|---|---|---|
Market Cap | $32.69B | $2.87B |
Sector | Health | Technology |
52-Week High | $92.22 | $34.87 |
52-Week Low | $62.02 | $17.33 |
Enterprise Value | $36.28B | $3.76B |
Dividend Yield | 0.54% | 9.87% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
TRMD trades at $27.99, up 1.05% today, with neutral technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.21 and P/B of 1.26, supported by robust profitability including 24.41% net margin and 15.62% ROE. Recent earnings showed mixed results with Q4 2025 beat but Q1 2026 miss, while Q2 2026 expectations are set at $3.3 EPS. The company maintains strong cash generation with $498.9M operating cash flow in 2025 and recently declared a $0.70 dividend.
Outlook remains positive with 100% analyst buy ratings and improving 2026 revenue guidance to $1.4B. Key opportunities include undervaluation relative to peers and strong dividend yield near 9%. Risks include earnings volatility from tanker market fluctuations and negative net cash flow trends. The stock presents value for income-focused investors despite cyclical industry exposure.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →